For patients who need a new aortic valve but who are poor candidates for either surgery or transcatheter aortic-valve replacement (TAVR) through femoral-artery access, the Cooper Heart Institute now offers a new approach called transcaval TAVR. Read more.
Until recently, high-risk heart patients with a severe form of leaky mitral valve disorder, called mitral regurgitation, and who were deemed too frail or sick to undergo open heart surgery had few treatment choices.
Now, because of Cooper Heart Institute’s (CHI) expertise in performing minimally invasive valve techniques and clinical research experience, the CHI is one of 75 testing sites in North America and the only site in South Jersey to be taking part in a clinical trial – the Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT) trial — to evaluate the effectiveness of a minimally invasive, catheter-based procedure that uses a clip to repair the leakage. Read more.